Sunitinib versus interferon-á in metastatic RCC

Jason Faris and Dror Michaelson

Motzer and colleagues presented updated results from a multicentre, phase III trial of sunitinib versus interferon-á as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.


*


UA-77507851-1